Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 17k
13 August 2018
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-003721/2018

The Commission is aware of the risks of falsified medicines through Internet sales. Since 1 July 2015, a common, EU-wide logo is mandatory for all online pharmacies or retailers legally operating in the EU. This makes it easier to distinguish between legal and illegal online pharmacies throughout the EU.

The Commission led a proactive communication campaign for the introduction of the EU common logo to identify legal online pharmacies. This included a Commission toolbox in all EU languages that was shared with Member States in order to ensure that a consistent message is given to EU citizens.

The communication materials, explained the legal framework for online sales in the EU(1) including the fact that Member States are free to prohibit online sales of prescription medicines. It warned that a legally operating EU online retailer, if authorised or entitled to supply a prescription medicine, will always require a prescription. It stressed that a compliance with this legal requirement is one of the guarantees that the medicine bought online is authentic and safe.

The Commission website(2) remains a key tool to keep citizens informed of the ongoing work to address counterfeit and falsified medicines.

(1)Article 85c of Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, OJ L, 1.7.2011, 174/74.

Last updated: 14 August 2018Legal notice